Francesco Bellini
| Francesco Bellini | |
|---|---|
Francesco Bellini
|
|
| Born |
November 20, 1947 Ascoli Piceno, Italy, |
| Residence | Quebec, Canada, (immigrated 1967) |
| Nationality | Italian, Canadian |
| Fields |
research scientist administrator entrepreneur business man |
| Notable awards | Several awards received from 1987 to 2016 |
Francesco Bellini, OC OQ (born November 20, 1947) is research scientist, administrator, entrepreneur and Quebecer business man born in Italy, Ascoli Piceno, in 1947.
He is a pioneer scientist-entrepreneur in the Canadian bio-pharmaceutical industry, he was co-founder of Biochem Pharma, as well as Chairman & Chief Executive Officer from 1986 to 2001. He has authored or co-authored more than twenty-five patents over his 20-year career as a research scientist.
Born in 1947 in Ascoli Piceno, Italy, Bellini immigrated to Canada in 1967. He received his Bachelor of Science degree from Loyola College (now Concordia University) in 1972 and his doctorate in organic chemistry from University of New Brunswick in 1977. He is the author and co-author of some 30 patents and has published numerous articles and papers based on his research.
Francesco Bellini is chairman of Picchio International, a privately owned company investing mainly in the fields of healthcare. Bellini also serves as Chairman of Klox Technologies – a privately owned company currently developing innovative and highly effective therapeutic and cosmetic solutions for use in the fields of dentistry, dermatology and tissue repair; BELLUS Health – a publicly traded company [TSX:BLU] focusing on developing drugs for rare diseases; and FB Health – a privately owned company involved in the research, development and commercialization of innovative molecules for the prevention and treatment of diseases in the Psychiatric, Neurologic and Geriatric fields.
Until 2001, Bellini was chairman of BioChem Pharma, an industry leader in HIV and a biopharmaceutical company focused on infectious diseases and cancer, which he co-founded in 1986. BioChem discovered the antiviral drug Epivir (3TC), which to this day is the cornerstone for AIDS therapy. From 1968 to 1984, he worked as a researcher at the Canadian subsidiary of a multinational pharmaceutical company. In 1984, Bellini established the Biochemicals Division of the Institut Armand-Frappier at the Université du Québec, specializing in research, manufacturing and the commercialization of fine chemicals which in 1986 became BioChem Pharma and in 2001 was successively acquired by Shire plc for $6 billion.
...
Wikipedia